Essential roles of E3 ubiquitin ligases in p53 regulation

International Journal of Molecular Sciences

Volumn 18, Issue 2, 2017, Pages

  Sane, Sanam ^a   Rezvani, Khosrow ^a  

^a UNIVERSITY OF SOUTH DAKOTA   (United States)

Author keywords

Apoptosis; Cancer therapy; E3 ubiquitin ligases; p53 tumor suppressor protein; Tumor

Indexed keywords

PROTEIN P53; UBIQUITIN PROTEIN LIGASE E3; PROTEIN BINDING; UBIQUITIN PROTEIN LIGASE;

ACUTE MYELOID LEUKEMIA; CANCER THERAPY; CELL PROLIFERATION; DNA DAMAGE; DOWN REGULATION; HUMAN; LIVER CELL CARCINOMA; PHOTOMORPHOGENESIS; PROMYELOCYTIC LEUKEMIA; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN STABILITY; REVIEW; ANIMAL; BIOLOGICAL MODEL; METABOLISM;

ANIMALS; HUMANS; MODELS, BIOLOGICAL; PROTEIN BINDING; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN-PROTEIN LIGASES;

EID: 85013345312     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms18020442     Document Type: Review

References (148)

1. Jenkins, L.M.; Durell, S.R.; Mazur, S.J.; Appella, E. p53 N-terminal phosphorylation: A defining layer of complex regulation. Carcinogenesis 2012, 33, 1441–1449.
2. Weinberg, R.L.; Veprintsev, D.B.; Bycroft, M.; Fersht, A.R. Comparative binding of p53 to its promoter and DNA recognition elements. J. Mol. Biol. 2005, 348, 589–596.
3. Joerger, A.C.; Fersht, A.R. The tumor suppressor p53: From structures to drug discovery. Cold Spring Harb. Perspect. Biol. 2010, 2, a000919.
4. Chene, P. The role of tetramerization in p53 function. Oncogene 2001, 20, 2611–2617.
5. Bakalkin, G.; Selivanova, G.; Yakovleva, T.; Kiseleva, E.; Kashuba, E.; Magnusson, K.P.; Szekely, L.; Klein, G.; Terenius, L.; Wiman, K.G. p53 binds single-stranded DNA ends through the C-terminal domain and internal DNA segments via the middle domain. Nucleic Acids Res. 1995, 23, 362–369.
6. Bieging, K.T.; Mello, S.S.; Attardi, L.D. Unravelling mechanisms of p53-mediated tumour suppression. Nat. Rev. Cancer 2014, 14, 359–370.
7. Vousden, K.H.; Prives, C. Blinded by the light: The growing complexity of p53. Cell 2009, 137, 413–431.
8. O’Brate, A.; Giannakakou, P. The importance of p53 location: Nuclear or cytoplasmic zip code? Drug Resist. Updates 2003, 6, 313–322.
9. Ashcroft, M.; Taya, Y.; Vousden, K.H. Stress signals utilize multiple pathways to stabilize p53. Mol. Cell. Biol. 2000, 20, 3224–3233.
10. Inoue, T.; Wu, L.; Stuart, J.; Maki, C.G. Control of p53 nuclear accumulation in stressed cells. FEBS Lett. 2005, 579, 4978–4984.
11. Bode, A.M.; Dong, Z. Post-translational modification of p53 in tumorigenesis. Nat. Rev. Cancer 2004, 4, 793–805.
12. Maki, C.G. p53 Localization. In p53; Springer: Boston, MA, USA, 2010; pp. 117–126.
13. Lane, D.P.; Cheok, C.F.; Lain, S. p53-based cancer therapy. Cold Spring Harb. Perspect. Biol. 2010, 2, a001222.
14. Bossi, G.; Sacchi, A. Restoration of wild-type p53 function in human cancer: Relevance for tumor therapy. Head Neck 2007, 29, 272–284.
15. Zhang, Q.; Zeng, S.X.; Lu, H. Targeting p53–Mdm2–Mdmx loop for cancer therapy. Subcell. Biochem. 2014, 85, 281–319.
16. Freedman, D.A.; Wu, L.; Levine, A.J. Functions of the Mdm2 oncoprotein. Cell. Mol. Life Sci. 1999, 55, 96–107.
17. Momand, J.; Wu, H.H.; Dasgupta, G. Mdm2—Master regulator of the p53 tumor suppressor protein. Gene 2000, 242, 15–29.
18. Wu, X.; Bayle, J.H.; Olson, D.; Levine, A.J. The p53–Mdm2 autoregulatory feedback loop. Genes Dev. 1993, 7, 1126–1132.
19. Kubbutat, M.H.; Jones, S.N.; Vousden, K.H. Regulation of p53 stability by Mdm2. Nature 1997, 387, 299–303.
20. Li, M.; Brooks, C.L.; Wu-Baer, F.; Chen, D.; Baer, R.; Gu, W. Mono-versus polyubiquitination: Differential control of p53 fate by Mdm2. Science 2003, 302, 1972–1975.
21. Wade, M.; Li, Y.C.; Matani, A.S.; Braun, S.M.; Milanesi, F.; Rodewald, L.W.; Wahl, G.M. Functional analysis and consequences of Mdm2 E3 ligase inhibition in human tumor cells. Oncogene 2012, 31, 4789–4797.
22. Nie, L.; Sasaki, M.; Maki, C.G. Regulation of p53 nuclear export through sequential changes in conformation and ubiquitination. J. Biol. Chem. 2007, 282, 14616–14625.
23. Geyer, R.K.; Yu, Z.K.; Maki, C.G. The Mdm2 RING-finger domain is required to promote p53 nuclear export. Nat. Cell Biol. 2000, 2, 569–573.
24. Jones, S.N.; Hancock, A.R.; Vogel, H.; Donehower, L.A.; Bradley, A. Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. Proc. Natl. Acad. Sci. USA 1998, 95, 15608–15612.
25. Bouska, A.; Eischen, C.M. Murine double minute 2: p53-independent roads lead to genome instability or death. Trends Biochem. Sci. 2009, 34, 279–286.
26. Nakayama, T.; Toguchida, J.; Wadayama, B.; Kanoe, H.; Kotoura, Y.; Sasaki, M.S. Mdm2 gene amplification in bone and soft-tissue tumors: Association with tumor progression in differentiated adipose-tissue tumors. Int. J. Cancer 1995, 64, 342–346.
27. Cordon-Cardo, C.; Latres, E.; Drobnjak, M.; Oliva, M.R.; Pollack, D.; Woodruff, J.M.; Marechal, V.; Chen, J.; Brennan, M.F.; Levine, A.J. Molecular abnormalities of Mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res. 1994, 54, 794–799.
28. Vassilev, L.T. Mdm2 inhibitors for cancer therapy. Trends Mol. Med. 2007, 13, 23–31.
29. Miller, C.W.; Aslo, A.; Won, A.; Tan, M.; Lampkin, B.; Koeffler, H.P. Alterations of the p53, Rb and Mdm2 genes in osteosarcoma. J. Cancer Res. Clin. Oncol. 1996, 122, 559–565.
30. Reifenberger, G.; Liu, L.; Ichimura, K.; Schmidt, E.E.; Collins, V.P. Amplification and overexpression of the Mdm2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res. 1993, 53, 2736–2739.
31. Watanabe, T.; Hotta, T.; Ichikawa, A.; Kinoshita, T.; Nagai, H.; Uchida, T.; Murate, T.; Saito, H. The Mdm2 oncogene overexpression in chronic lymphocytic leukemia and low-grade lymphoma of B-cell origin. Blood 1994, 84, 3158–3165.
32. Rayburn, E.; Zhang, R.; He, J.; Wang, H. Mdm2 and human malignancies: Expression, clinical pathology, prognostic markers, and implications for chemotherapy. Curr. Cancer Drug Targets 2005, 5, 27–41.
33. Burgess, A.; Chia, K.M.; Haupt, S.; Thomas, D.; Haupt, Y.; Lim, E. Clinical overview of Mdm2/x-targeted therapies. Front. Oncol. 2016, 6, 7.
34. Kojima, K.; Konopleva, M.; Samudio, I.J.; Shikami, M.; Cabreira-Hansen, M.; McQueen, T.; Ruvolo, V.; Tsao, T.; Zeng, Z.; Vassilev, L.T.; et al. Mdm2 antagonists induce p53-dependent apoptosis in AML: Implications for leukemia therapy. Blood 2005, 106, 3150–3159.
35. Secchiero, P.; di Iasio, M.G.; Gonelli, A.; Zauli, G. The Mdm2 inhibitor Nutlins as an innovative therapeutic tool for the treatment of haematological malignancies. Curr. Pharm. Des. 2008, 14, 2100–2110.
36. Van Maerken, T.; Ferdinande, L.; Taildeman, J.; Lambertz, I.; Yigit, N.; Vercruysse, L.; Rihani, A.; Michaelis, M.; Cinatl, J., Jr.; Cuvelier, C.A.; et al. Antitumor activity of the selective Mdm2 antagonist Nutlin-3 against chemoresistant neuroblastoma with wild-type p53. J. Natl. Cancer Inst. 2009, 101, 1562–1574.
37. Secchiero, P.; Bosco, R.; Celeghini, C.; Zauli, G. Recent advances in the therapeutic perspectives of Nutlin-3. Curr. Pharm. Des. 2011, 17, 569–577.
38. Zhao, Y.; Yu, H.; Hu, W. The regulation of Mdm2 oncogene and its impact on human cancers. Acta Biochim. Biophys. Sin. 2014, 46, 180–189.
39. Cheok, C.F.; Verma, C.S.; Baselga, J.; Lane, D.P. Translating p53 into the clinic. Nat. Rev. Clin. Oncol. 2011, 8, 25–37.
40. Jones, S.N.; Roe, A.E.; Donehower, L.A.; Bradley, A. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 1995, 378, 206–208.
41. Bunderson-Schelvan, M.; Erbe, A.K.; Schwanke, C.; Pershouse, M.A. Suppression of the mouse double minute 4 gene causes changes in cell cycle control in a human mesothelial cell line responsive to ultraviolet radiation exposure. Environ. Mol. Mutagen. 2009, 50, 753–759.
42. Wade, M.; Wang, Y.V.; Wahl, G.M. The p53 orchestra: Mdm2 and Mdmx set the tone. Trends Cell Biol. 2010, 20, 299–309.
43. Brown, C.J.; Lain, S.; Verma, C.S.; Fersht, A.R.; Lane, D.P. Awakening guardian angels: Drugging the p53 pathway. Nat. Rev. Cancer 2009, 9, 862–873.
44. Wang, X.; Wang, J.; Jiang, X. MdmX protein is essential for Mdm2 protein-mediated p53 polyubiquitination. J. Biol. Chem. 2011, 286, 23725–23734.
45. Li, Q.; Lozano, G. Molecular pathways: Targeting Mdm2 and Mdm4 in cancer therapy. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2013, 19, 34–41.
46. Wang, L.; He, G.; Zhang, P.; Wang, X.; Jiang, M.; Yu, L. Interplay between Mdm2, Mdmx, Pirh2 and COP1: The negative regulators of p53. Mol. Biol. Rep. 2011, 38, 229–236.
47. Zhang, Y.; Xiong, Y.; Yarbrough, W.G. ARF promotes Mdm2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 1998, 92, 725–734.
48. Sherr, C.J.; Weber, J.D. The ARF/p53 pathway. Curr. Opin. Genet. Dev. 2000, 10, 94–99.
49. Christophorou, M.A.; Ringshausen, I.; Finch, A.J.; Swigart, L.B.; Evan, G.I. The pathological response to DNA damage does not contribute to p53-mediated tumour suppression. Nature 2006, 443, 214–217.
50. Efeyan, A.; Murga, M.; Martinez-Pastor, B.; Ortega-Molina, A.; Soria, R.; Collado, M.; Fernandez-Capetillo, O.; Serrano, M. Limited role of murine ATM in oncogene-induced senescence and p53-dependent tumor suppression. PLoS ONE 2009, 4, e5475.
51. Halazonetis, T.D.; Gorgoulis, V.G.; Bartek, J. An oncogene-induced DNA damage model for cancer development. Science 2008, 319, 1352–1355.
52. Wang, X.; Zha, M.; Zhao, X.; Jiang, P.; Du, W.; Tam, A.Y.; Mei, Y.; Wu, M. Siva1 inhibits p53 function by acting as an ARF E3 ubiquitin ligase. Nat. Commun. 2013, 4, 1551.
53. Park, I.K.; Blum, W.; Baker, S.D.; Caligiuri, M.A. E3 ubiquitin ligase Cbl-b activates the p53 pathway by targeting Siva1, a negative regulator of ARF, in FLT3 inhibitor-resistant acute myeloid leukemia. Leukemia 2016, 31, 502–505.
54. Wang, C.; Ivanov, A.; Chen, L.; Fredericks, W.J.; Seto, E.; Rauscher, F.J.; Chen, J. Mdm2 interaction with nuclear corepressor KAP1 contributes to p53 inactivation. EMBO J. 2005, 24, 3279–3290.
55. Joo, H.M.; Kim, J.Y.; Jeong, J.B.; Seong, K.M.; Nam, S.Y.; Yang, K.H.; Kim, C.S.; Kim, H.S.; Jeong, M.; An, S.; et al. Ret finger protein 2 enhances ionizing radiation-induced apoptosis via degradation of AKT and Mdm2. Eur. J. Cell Biol. 2011, 90, 420–431.
56. Bernardi, R.; Scaglioni, P.P.; Bergmann, S.; Horn, H.F.; Vousden, K.H.; Pandolfi, P.P. PML regulates p53 stability by sequestering Mdm2 to the nucleolus. Nat. Cell Biol. 2004, 6, 665–672.
57. Xie, N.; Ma, L.; Zhu, F.; Zhao, W.; Tian, F.; Yuan, F.; Fu, J.; Huang, D.; Lv, C.; Tong, T. Regulation of the Mdm2-p53 pathway by the nucleolar protein CSIG in response to nucleolar stress. Sci. Rep. 2016, 6, 36171.
58. Yang, Q.; Liao, L.; Deng, X.; Chen, R.; Gray, N.S.; Yates, J.R.; Lee, J.D. BMK1 is involved in the regulation of p53 through disrupting the PML-Mdm2 interaction. Oncogene 2013, 32, 3156–3164.
59. Simerzin, A.; Zorde-Khvalevsky, E.; Rivkin, M.; Adar, R.; Zucman-Rossi, J.; Couchy, G.; Roskams, T.; Govaere, O.; Oren, M.; Giladi, H.; et al. The liver-specific microRNA-122*, the complementary strand of microRNA-122, acts as a tumor suppressor by modulating the p53/mouse double minute 2 homolog circuitry. Hepatology 2016, 64, 1623–1636.
60. Shangary, S.; Qin, D.; McEachern, D.; Liu, M.; Miller, R.S.; Qiu, S.; Nikolovska-Coleska, Z.; Ding, K.; Wang, G.; Chen, J.; et al. Temporal activation of p53 by a specific Mdm2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc. Natl. Acad. Sci. USA 2008, 105, 3933–3938.
61. Kojima, K.; Konopleva, M.; McQueen, T.; O’Brien, S.; Plunkett, W.; Andreeff, M. Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome ATM-mediated resistance to fludarabine in chronic lymphocytic leukemia. Blood 2006, 108, 993–1000.
62. Pichiorri, F.; Suh, S.-S.; Rocci, A.; De Luca, L.; Taccioli, C.; Santhanam, R.; Zhou, W.; Benson, D.M., Jr.; Hofmainster, C.; Alder, H.; et al. Downregulation of p53-inducible microRNAs 192, 194, and 215 Impairs the p53/Mdm2 Autoregulatory Loop in Multiple Myeloma Development. Cancer Cell 2010, 18, 367–381.
63. Xiao, J.; Lin, H.; Luo, X.; Luo, X.; Wang, Z. miR-605 joins p53 network to form a p53:miR-605:Mdm2 positive feedback loop in response to stress. EMBO J. 2011, 30, 5021.
64. Dar, A.A.; Majid, S.; Rittsteuer, C.; de Semir, D.; Bezrookove, V.; Tong, S.; Nosrati, M.; Sagebiel, R.; Miller, J.R., III; Kashani-Sabet, M. The role of miR-18b in Mdm2-p53 pathway signaling and melanoma progression. J. Natl. Cancer Inst. 2013, 105, 433–442.
65. ′ UTR of Mdm4 affects ovarian cancer progression and chemosensitivity. Cancer Res. 2010, 70, 9641–9649.
66. Ovcharenko, D.; Stolzel, F.; Poitz, D.; Fierro, F.; Schaich, M.; Neubauer, A.; Kelnar, K.; Davison, T.; Muller-Tidow, C.; Thiede, C.; et al. miR-10a overexpression is associated with NPM1 mutations and Mdm4 downregulation in intermediate-risk acute myeloid leukemia. Exp. Hematol. 2011, 39, 1030–1042.
67. Hoffman, Y.; Bublik, D.R.; Pilpel, Y.; Oren, M. miR-661 downregulates both Mdm2 and Mdm4 to activate p53. Cell Death Differ. 2014, 21, 302–309.
68. Mandke, P.; Wyatt, N.; Fraser, J.; Bates, B.; Berberich, S.J.; Markey, M.P. MicroRNA-34a modulates Mdm4 expression via a target site in the open reading frame. PLoS ONE 2012, 7, e42034.
69. Stegeman, S.; Moya, L.; Selth, L.A.; Spurdle, A.B.; Clements, J.A.; Batra, J. A genetic variant of Mdm4 influences regulation by multiple microRNAs in prostate cancer. Endocr. Relat. Cancer 2015, 22, 265–276.
70. Xie, C.; Chen, W.; Zhang, M.; Cai, Q.; Xu, W.; Li, X.; Jiang, S. Mdm4 regulation by the let-7 miRNA family in the DNA damage response of glioma cells. FEBS Lett. 2015, 589, 1958–1965.
71. Vijayakumaran, R.; Tan, K.H.; Miranda, P.J.; Haupt, S.; Haupt, Y. Regulation of mutant p53 protein expression. Front. Oncol. 2015, 5, 284.
72. Hoffman, Y.; Pilpel, Y.; Oren, M. microRNAs and Alu elements in the p53–Mdm2–Mdm4 regulatory network. J. Mol. Cell Biol. 2014, 6, 192–197.
73. Yang, H.Y.; Wen, Y.Y.; Chen, C.H.; Lozano, G.; Lee, M.H. 14-3-3σ positively regulates p53 and suppresses tumor growth. Mol. Cell. Biol. 2003, 23, 7096–7107.
74. Stevenson, L.F.; Sparks, A.; Allende-Vega, N.; Xirodimas, D.P.; Lane, D.P.; Saville, M.K. The deubiquitinating enzyme USP2a regulates the p53 pathway by targeting Mdm2. EMBO J. 2007, 26, 976–986.
75. Zhang, Y.; Wolf, G.W.; Bhat, K.; Jin, A.; Allio, T.; Burkhart, W.A.; Xiong, Y. Ribosomal protein L11 negatively regulates oncoprotein Mdm2 and mediates a p53-dependent ribosomal-stress checkpoint pathway. Mol. Cell. Biol. 2003, 23, 8902–8912.
76. Zheng, J.; Lang, Y.; Zhang, Q.; Cui, D.; Sun, H.; Jiang, L.; Chen, Z.; Zhang, R.; Gao, Y.; Tian, W.; et al. Structure of human Mdm2 complexed with RPL11 reveals the molecular basis of p53 activation. Genes Dev. 2015, 29, 1524–1534.
77. Sasaki, M.; Kawahara, K.; Nishio, M.; Mimori, K.; Kogo, R.; Hamada, K.; Itoh, B.; Wang, J.; Komatsu, Y.; Yang, Y.R.; et al. Regulation of the Mdm2–P53 pathway and tumor growth by PICT1 via nucleolar RPL11. Nat. Med. 2011, 17, 944–951.
78. Sui, G.; Affar el, B.; Shi, Y.; Brignone, C.; Wall, N.R.; Yin, P.; Donohoe, M.; Luke, M.P.; Calvo, D.; Grossman, S.R.; et al. Yin Yang 1 is a negative regulator of p53. Cell 2004, 117, 859–872.
79. Gottlieb, T.M.; Leal, J.F.; Seger, R.; Taya, Y.; Oren, M. Cross-talk between Akt, p53 and Mdm2: Possible implications for the regulation of apoptosis. Oncogene 2002, 21, 1299–1303.
80. Xirodimas, D.P.; Saville, M.K.; Bourdon, J.C.; Hay, R.T.; Lane, D.P. Mdm2-mediated NEDD8 conjugation of p53 inhibits its transcriptional activity. Cell 2004, 118, 83–97.
81. Koegl, M.; Hoppe, T.; Schlenker, S.; Ulrich, H.D.; Mayer, T.U.; Jentsch, S. A novel ubiquitination factor, E4, is involved in multiubiquitin chain assembly. Cell 1999, 96, 635–644.
82. Shi, D.; Pop, M.S.; Kulikov, R.; Love, I.M.; Kung, A.L.; Grossman, S.R. CBP and p300 are cytoplasmic E4 polyubiquitin ligases for p53. Proc. Natl. Acad. Sci. USA 2009, 106, 16275–16280.
83. Grossman, S.R.; Deato, M.E.; Brignone, C.; Chan, H.M.; Kung, A.L.; Tagami, H.; Nakatani, Y.; Livingston, D.M. Polyubiquitination of p53 by a ubiquitin ligase activity of p300. Science 2003, 300, 342–344.
84. Wu, H.; Pomeroy, S.L.; Ferreira, M.; Teider, N.; Mariani, J.; Nakayama, K.I.; Hatakeyama, S.; Tron, V.A.; Saltibus, L.F.; Spyracopoulos, L.; et al. UBE4B promotes Hdm2-mediated degradation of the tumor suppressor p53. Nat. Med. 2011, 17, 347–355.
85. Deng, X.W.; Caspar, T.; Quail, P.H. cop1: A regulatory locus involved in light-controlled development and gene expression in Arabidopsis. Genes Dev. 1991, 5, 1172–1182.
86. Bianchi, E.; Denti, S.; Catena, R.; Rossetti, G.; Polo, S.; Gasparian, S.; Putignano, S.; Rogge, L.; Pardi, R. Characterization of human constitutive photomorphogenesis protein 1, a RING finger ubiquitin ligase that interacts with Jun transcription factors and modulates their transcriptional activity. J. Biol. Chem. 2003, 278, 19682–19690.
87. Marine, J.-C. Spotlight on the role of COP1 in tumorigenesis. Nat. Rev. Cancer 2012, 12, 455–464.
88. Li, Y.F.; Wang, D.D.; Zhao, B.W.; Wang, W.; Huang, C.Y.; Chen, Y.M.; Zheng, Y.; Keshari, R.P.; Xia, J.C.; Zhou, Z.W. High level of COP1 expression is associated with poor prognosis in primary gastric cancer. Int. J. Biol. Sci. 2012, 8, 1168–1177.
89. Li, J.; Wang, L.; Xiao, R.; Pan, Q.; Huang, H.; Kuang, R. High expression of constitutive photomorphogenic 1 (COP1) is associated with poor prognosis in bladder cancer. Tumour Biol. 2016, 37, 8917–8922.
90. Zou, S.; Zhu, Y.; Wang, B.; Qian, F.; Zhang, X.; Wang, L.; Fu, C.; Bao, H.; Xie, M.; Gao, S.; et al. The ubiquitin ligase COP1 promotes glioma cell proliferation by preferentially downregulating tumor suppressor p53. Mol. Neurobiol. 2016.
91. Dornan, D.; Bheddah, S.; Newton, K.; Ince, W.; Frantz, G.D.; Dowd, P.; Koeppen, H.; Dixit, V.M.; French, D.M. COP1, the negative regulator of p53, is overexpressed in breast and ovarian adenocarcinomas. Cancer Res. 2004, 64, 7226–7230.
92. Dornan, D.; Wertz, I.; Shimizu, H.; Arnott, D.; Frantz, G.D.; Dowd, P.; O’Rourke, K.; Koeppen, H.; Dixit, V.M. The ubiquitin ligase COP1 is a critical negative regulator of p53. Nature 2004, 429, 86–92.
93. Vleugel, M.M.; Greijer, A.E.; Bos, R.; van der Wall, E.; van Diest, P.J. c-Jun activation is associated with proliferation and angiogenesis in invasive breast cancer. Hum. Pathol. 2006, 37, 668–674.
94. Wertz, I.E.; O’Rourke, K.M.; Zhang, Z.; Dornan, D.; Arnott, D.; Deshaies, R.J.; Dixit, V.M. Human De-etiolated-1 regulates c-Jun by assembling a CUL4A ubiquitin ligase. Science 2004, 303, 1371–1374.
95. Shao, J.; Teng, Y.; Padia, R.; Hong, S.; Noh, H.; Xie, X.; Mumm, J.S.; Dong, Z.; Ding, H.F.; Cowell, J.; et al. COP1 and GSK3β cooperate to promote c-Jun degradation and inhibit breast cancer cell tumorigenesis. Neoplasia 2013, 15, 1075–1085.
96. Lee, Y.H.; Andersen, J.B.; Song, H.T.; Judge, A.D.; Seo, D.; Ishikawa, T.; Marquardt, J.U.; Kitade, M.; Durkin, M.E.; Raggi, C.; et al. Definition of ubiquitination modulator COP1 as a novel therapeutic target in human hepatocellular carcinoma. Cancer Res. 2010, 70, 8264–8269.
97. Migliorini, D.; Bogaerts, S.; Defever, D.; Vyas, R.; Denecker, G.; Radaelli, E.; Zwolinska, A.; Depaepe, V.; Hochepied, T.; Skarnes, W.C.; et al. COP1 constitutively regulates c-Jun protein stability and functions as a tumor suppressor in mice. J. Clin. Investig. 2011, 121, 1329–1343.
98. Su, C.H.; Zhao, R.; Zhang, F.; Qu, C.; Chen, B.; Feng, Y.H.; Phan, L.; Chen, J.; Wang, H.; Wang, H.; et al. 14-3-3σ exerts tumor-suppressor activity mediated by regulation of COP1 stability. Cancer Res. 2011, 71, 884–894.
99. Jia, L.; Gorman, G.S.; Coward, L.U.; Noker, P.E.; McCormick, D.; Horn, T.L.; Harder, J.B.; Muzzio, M.; Prabhakar, B.; Ganesh, B.; et al. Preclinical pharmacokinetics, metabolism, and toxicity of azurin-p28 (NSC745104) a peptide inhibitor of p53 ubiquitination. Cancer Chemother. Pharmacol. 2011, 68, 513–524.
100. Apiyo, D.; Wittung-Stafshede, P. Unique complex between bacterial azurin and tumor-suppressor protein p53. Biochem. Biophys. Res. Commun. 2005, 332, 965–968.
101. Yamada, T.; Christov, K.; Shilkaitis, A.; Bratescu, L.; Green, A.; Santini, S.; Bizzarri, A.R.; Cannistraro, S.; Gupta, T.K.; Beattie, C.W. p28, a first in class peptide inhibitor of cop1 binding to p53. Br. J. Cancer 2013, 108, 2495–2504.
102. Leng, R.P.; Lin, Y.; Ma, W.; Wu, H.; Lemmers, B.; Chung, S.; Parant, J.M.; Lozano, G.; Hakem, R.; Benchimol, S. Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell 2003, 112, 779–791.
103. Chen, J.; Marechal, V.; Levine, A.J. Mapping of the p53 and Mdm-2 interaction domains. Mol. Cell. Biol. 1993, 13, 4107–4114.
104. Picksley, S.M.; Vojtesek, B.; Sparks, A.; Lane, D.P. Immunochemical analysis of the interaction of p53 with Mdm2—Fine mapping of the Mdm2 binding site on p53 using synthetic peptides. Oncogene 1994, 9, 2523–2529.
105. Poyurovsky, M.V.; Katz, C.; Laptenko, O.; Beckerman, R.; Lokshin, M.; Ahn, J.; Byeon, I.J.; Gabizon, R.; Mattia, M.; Zupnick, A.; et al. The C terminus of p53 binds the N-terminal domain of Mdm2. Nat. Struct. Mol. Biol. 2010, 17, 982–989.
106. Sheng, Y.; Laister, R.; Lemak, A.; Wu, B.; Tai, E.; Duan, S.; Lukin, J.; Sunnerhagen, M.; Srisailam, S.; Karra, M.; et al. Molecular basis of Pirh2-mediated p53 ubiquitylation. Nat. Struct. Mol. Biol. 2008, 15, 1334–1342.
107. Yang, Y.; Li, C.-C.H.; Weissman, A.M. Regulating the p53 system through ubiquitination. Oncogene 2004, 23, 2096–2106.
108. Logan, I.R.; Sapountzi, V.; Gaughan, L.; Neal, D.E.; Robson, C.N. Control of human PIRH2 protein stability: Involvement of Tip60 and the proteasome. J. Biol. Chem. 2004, 279, 11696–11704.
109. Hakem, A.; Bohgaki, M.; Lemmers, B.; Tai, E.; Salmena, L.; Matysiak-Zablocki, E.; Jung, Y.S.; Karaskova, J.; Kaustov, L.; Duan, S.; et al. Role of Pirh2 in mediating the regulation of p53 and c-Myc. PLoS Genet. 2011, 7, e1002360.
110. Meyer, N.; Penn, L.Z. Reflecting on 25 years with MYC. Nat. Rev. Cancer 2008, 8, 976–990.
111. Li, Q.; Lin, S.; Wang, X.; Lian, G.; Lu, Z.; Guo, H.; Ruan, K.; Wang, Y.; Ye, Z.; Han, J.; et al. Axin determines cell fate by controlling the p53 activation threshold after DNA damage. Nat. Cell Biol. 2009, 11, 1128–1134.
112. Sho, T.; Tsukiyama, T.; Sato, T.; Kondo, T.; Cheng, J.; Saku, T.; Asaka, M.; Hatakeyama, S. TRIM29 negatively regulates p53 via inhibition of Tip60. Biochim. Biophys. Acta 2011, 1813, 1245–1253.
113. Yang, G.; Gong, Y.; Wang, Q.; Wang, L.; Zhang, X. miR-100 antagonism triggers apoptosis by inhibiting ubiquitination-mediated p53 degradation. Oncogene 2016.
114. Logan, I.R.; Gaughan, L.; McCracken, S.R.; Sapountzi, V.; Leung, H.Y.; Robson, C.N. Human PIRH2 enhances androgen receptor signaling through inhibition of histone deacetylase 1 and is overexpressed in prostate cancer. Mol. Cell. Biol. 2006, 26, 6502–6510.
115. Duan, W.; Gao, L.; Druhan, L.J.; Zhu, W.G.; Morrison, C.; Otterson, G.A.; Villalona-Calero, M.A. Expression of Pirh2, a newly identified ubiquitin protein ligase, in lung cancer. J. Natl. Cancer Inst. 2004, 96, 1718–1721.
116. Kossatz, U.; Malek, N.P. p27: Tumor suppressor and oncogene…? Cell Res. 2007, 17, 832–833.
117. McDonough, H.; Patterson, C. CHIP: A link between the chaperone and proteasome systems. Cell Stress Chaperones 2003, 8, 303–308.
118. Esser, C.; Scheffner, M.; Hohfeld, J. The chaperone-associated ubiquitin ligase CHIP is able to target p53 for proteasomal degradation. J. Biol. Chem. 2005, 280, 27443–27448.
119. Elengoe, A.; Naser, M.A.; Hamdan, S. A novel protein interaction between nucleotide binding domain of Hsp70 and p53 motif. Int. J. Genom. 2015, 2015, 391293.
120. Fourie, A.M.; Hupp, T.R.; Lane, D.P.; Sang, B.C.; Barbosa, M.S.; Sambrook, J.F.; Gething, M.J.H. Hsp70 binding sites in the tumor suppressor protein p53. J. Biol. Chem. 1997, 272, 19471–19479.
121. Stankiewicz, M.; Nikolay, R.; Rybin, V.; Mayer, M.P. CHIP participates in protein triage decisions by preferentially ubiquitinating Hsp70-bound substrates. FEBS J. 2010, 277, 3353–3367.
122. Muller, P.; Hrstka, R.; Coomber, D.; Lane, D.P.; Vojtesek, B. Chaperone-dependent stabilization and degradation of p53 mutants. Oncogene 2008, 27, 3371–3383.
123. Li, D.; Marchenko, N.D.; Schulz, R.; Fischer, V.; Velasco-Hernandez, T.; Talos, F.; Moll, U.M. Functional inactivation of endogenous Mdm2 and CHIP by HSP90 causes aberrant stabilization of mutant p53 in human cancer cells. Mol. Cancer Res. 2011, 9, 577–588.
124. Davenport, J.; Manjarrez, J.R.; Peterson, L.; Krumm, B.; Blagg, B.S.; Matts, R.L. Gambogic acid, a natural product inhibitor of Hsp90. J. Nat. Prod. 2011, 74, 1085–1092.
125. Wang, J.; Zhao, Q.; Qi, Q.; Gu, H.Y.; Rong, J.J.; Mu, R.; Zou, M.J.; Tao, L.; You, Q.D.; Guo, Q.L. Gambogic acid-induced degradation of mutant p53 is mediated by proteasome and related to CHIP. J. Cell. Biochem. 2011, 112, 509–519.
126. McDonough, H.; Charles, P.C.; Hilliard, E.G.; Qian, S.B.; Min, J.N.; Portbury, A.; Cyr, D.M.; Patterson, C. Stress-dependent Daxx-CHIP interaction suppresses the p53 apoptotic program. J. Biol. Chem. 2009, 284, 20649–20659.
127. Sisoula, C.; Trachana, V.; Patterson, C.; Gonos, E.S. CHIP-dependent p53 regulation occurs specifically during cellular senescence. Free Radic. Biol. Med. 2011, 50, 157–165.
128. Naito, A.T.; Okada, S.; Minamino, T.; Iwanaga, K.; Liu, M.L.; Sumida, T.; Nomura, S.; Sahara, N.; Mizoroki, T.; Takashima, A.; et al. Promotion of CHIP-mediated p53 degradation protects the heart from ischemic injury. Circ. Res. 2010, 106, 1692–1702.
129. Parrales, A.; Ranjan, A.; Iyer, S.V.; Padhye, S.; Weir, S.J.; Roy, A.; Iwakuma, T. DNAJA1 controls the fate of misfolded mutant p53 through the mevalonate pathway. Nat. Cell Biol. 2016, 18, 1233–1243.
130. Rosser, M.F.; Washburn, E.; Muchowski, P.J.; Patterson, C.; Cyr, D.M. Chaperone functions of the E3 ubiquitin ligase CHIP. J. Biol. Chem. 2007, 282, 22267–22277.
131. Tripathi, V.; Ali, A.; Bhat, R.; Pati, U. CHIP chaperones wild type p53 tumor suppressor protein. J. Biol. Chem. 2007, 282, 28441–28454.
132. Black, J.D.; Rezvani, K. Heat shock protein 70s as potential molecular targets for colon cancer therapeutics. Curr. Med. Chem. 2016, 23, 3171–3188.
133. Kaul, S.C.; Deocaris, C.C.; Wadhwa, R. Three faces of mortalin: A housekeeper, guardian and killer. Exp. Gerontol. 2007, 42, 263–274.
134. Wadhwa, R.; Ryu, J.; Ahn, H.M.; Saxena, N.; Chaudhary, A.; Yun, C.O.; Kaul, S.C. Functional significance of point mutations in stress chaperone mortalin and their relevance to Parkinson disease. J. Biol. Chem. 2015, 290, 8447–8456.
135. Sane, S.; Abdullah, A.; Boudreau, D.A.; Autenried, R.K.; Gupta, B.K.; Wang, X.; Wang, H.; Schlenker, E.H.; Zhang, D.; Telleria, C.; et al. Ubiquitin-like (UBX)-domain-containing protein, UBXN2A, promotes cell death by interfering with the p53-Mortalin interactions in colon cancer cells. Cell Death Dis. 2014, 5, e1118.
136. Sane, S.; Abdullah, A.; Nelson, M.E.; Wang, H.; Chauhan, S.C.; Newton, S.S.; Rezvani, K. Structural studies of UBXN2A and mortalin interaction and the putative role of silenced UBXN2A in preventing response to chemotherapy. Cell Stress Chaperones 2016, 21, 313–326.
137. Levine, A.J.; Oren, M. The first 30 years of p53: Growing ever more complex. Nat. Rev. Cancer 2009, 9, 749–758.
138. Vousden, K.H.; Ryan, K.M. p53 and metabolism. Nat. Rev. Cancer 2009, 9, 691–700.
139. Vogelstein, B.; Lane, D.; Levine, A.J. Surfing the p53 network. Nature 2000, 408, 307–310.
140. Hollstein, M.; Sidransky, D.; Vogelstein, B.; Harris, C.C. p53 mutations in human cancers. Science 1991, 253, 49–53.
141. Peller, S.; Rotter, V. TP53 in hematological cancer: Low incidence of mutations with significant clinical relevance. Hum. Mutat. 2003, 21, 277–284.
142. Schuijer, M.; Berns, E.M. TP53 and ovarian cancer. Hum. Mutat. 2003, 21, 285–291.
143. Iacopetta, B. TP53 mutation in colorectal cancer. Hum. Mutat. 2003, 21, 271–276.
144. Lain, S.; Lane, D. Improving cancer therapy by non-genotoxic activation of p53. Eur. J. Cancer 2003, 39, 1053–1060.
145. Jain, A.K.; Barton, M.C. Making sense of ubiquitin ligases that regulate p53. Cancer Biol. Ther. 2010, 10, 665–672.
146. Brooks, C.L.; Gu, W. p53 regulation by ubiquitin. FEBS Lett. 2011, 585, 2803–2809.
147. Lee, J.T.; Gu, W. The multiple levels of regulation by p53 ubiquitination. Cell Death Differ. 2010, 17, 86–92. [CrossRef] [PubMed]
148. Mackay, H.; Hedley, D.; Major, P.; Townsley, C.; Mackenzie, M.; Vincent, M.; Degendorfer, P.; Tsao, M.S.; Nicklee, T.; Birle, D.; et al. A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancer. Clin. Cancer Res. 2005, 11, 5526–5533.